Comparing the efficacy of hexapeptide and azoximer bromide in coprehensive treatment of children with secondary pyelonephritis

Abstract

Objective. Secondary pyelonephritis occurs in children in a distant period after adequate surgical correction of congenital obstructive pathology due to long-lasting shifts of immunologic resistance. Patients and methods. The authors treated 80 children aged 5 to 15 years with secondary pyelonephritis with preserved renal function against hydronephrosis, megaureter, vesicoureteral reflux. Immunological parameters were assessed at the child's admission to the hospital and 3 months after in-patient treatment. Initial changes of immunological reactivity in the patients substantiated the treatment tactics. Group 1 consisted of 40 patients, whose complex treatment included the immunomodulator, the active ingredient hexapeptide; Group 2 consisted of 40 patients, whose complex treatment included the tablet preparation of Polyoxidonium, the active ingredient azoximer bromide. Results. Inclusion of and azoximer bromide in treatment of children with secondary pyelonephritis was found to lead to increasing of IgA, IgG, B-cells amount, phagocytosis rate and natural killer number; and to decreasing of the amount of T-lymphocytes and CD4-cells. Inclusion of hexapeptide in treatment of secondary pyelonephritis in children increases level of phagocytic activity of neutrophils, amount of natural killer cells, CD3–/CD19+-cells, CD3+/CD4+-lymphocytes number. Conclusion. Inclusion of immunotropic preparations in complex treatment of secondary pyelonephritis in children is justified in case of detection of above-mentioned disturbances. Key words: secondary pyelonephritis, immunocorrection, hexapeptid, children, azoximer bromide